This SPAC merger targets the precision oncology space via Ignite's proteomics platform. Monitor for the S-4 registration statement filing and SPAC shareholder vote as key catalysts. Redemption levels from COPL's trust account will determine post-deal cash position — a key variable for valuation. Watch for any competing proposals during the go-shop period defined in the BCA.
Price Chart
Executive Summary
Copley Acquisition Corp (COPL) entered into a definitive business combination agreement to merge with Ignite Proteomics, a precision oncology proteomics company, via a SPAC merger. Ignite holders will receive $150M in Pubco common stock at $10.00/share, and the combined entity (Pubco) will list on NYSE. Copley's trust account held ~$179.5M as of March 31, 2026, and the deal requires at least $15M in available trust/ financing proceeds post-redemptions. The transaction is subject to shareholder approvals, SEC registration, and other customary closings, targeted for H2 2026.
Key Financial Metrics
Key Facts
- Copley entered into a Business Combination Agreement with Ignite Proteomics, a precision oncology proteomics company.
- Ignite holders to receive $150,000,000 in Pubco common stock at $10.00/share (15 million shares).
- Copley's trust account had ~$179.5M as of March 31, 2026.
- Minimum cash condition: SPAC must have at least $15M available post-redemptions plus any transaction financing.
- Sponsor payment of $4,000,000 to be made at closing.
- Copley to seek up to $20M in transaction financing; Ignite to seek up to $10M.
- Post-closing board will have 7 members, at least 4 independent; Ignite CEO to remain CEO.
- Lock-up: 90 days post-business combination for founders; amended insider letter executed.
- Aditxt Inc. (parent of Ignite) provided a guaranty of Ignite's obligations under the BCA.
- Closing expected H2 2026, subject to shareholder approvals, SEC effectiveness, and other conditions.
Financial Impact
Ignite holders to receive $150M in Pubco stock at $10/share. Copley trust account balance ~$179.5M (3/31/26). Transaction requires minimum $15M available cash post-redemptions. Up to $30M in additional transaction financing sought ($20M by Copley, $10M by Ignite).
Risk Factors
- High redemption rate could deplete trust account cash below minimum, jeopardizing closing.
- Transaction may fail to close by September 30, 2026 deadline (subject to extension for SEC review).
- Ignite is a pre-revenue or early-revenue-stage precision oncology company, carrying execution/regulatory risk.
- Stockholder or regulatory approval risks; SEC review of S-4 could delay timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-006336 |
| Document: copleyacq_8k.htm | 0001829126-26-006336 |
| Document: copleyacq_ex10-1.htm | 0001829126-26-006336 |
| Document: copleyacq_ex10-2.htm | 0001829126-26-006336 |
| Document: copleyacq_ex10-3.htm | 0001829126-26-006336 |
| Document: copleyacq_ex99-1.htm | 0001829126-26-006336 |
| Document: 0001829126-26-006336-index-headers.html | 0001829126-26-006336 |
| Document: 0001829126-26-006336-index.html | 0001829126-26-006336 |
| Document: 0001829126-26-006336.txt | 0001829126-26-006336 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.62 $10.60 | ▼ −0.19% | ▼ −0.27% | $10.60 (−0.19%) |
Oct 13, 2026 14d ago | 8-K | $10.57 $10.60 | ▼ −0.28% | ▲ +0.17% | $10.60 (−0.28%) |
Oct 9, 2026 18d ago | 8-K | $10.57 $10.59 | ▲ +0.19% | ▲ +1.68% | $10.60 (+0.28%) |
Jun 11, 2026 19w ago | 8-K | $10.42 $10.42 | · 0.00% | ▼ −0.43% | $10.60 (+1.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers